nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—psoriatic arthritis—psoriasis	0.134	0.232	CtDrD
Methotrexate—systemic scleroderma—psoriasis	0.13	0.223	CtDrD
Methotrexate—ankylosing spondylitis—psoriasis	0.111	0.191	CtDrD
Methotrexate—systemic lupus erythematosus—psoriasis	0.105	0.182	CtDrD
Methotrexate—rheumatoid arthritis—psoriasis	0.0996	0.172	CtDrD
Methotrexate—ABCC10—Cyclosporine—psoriasis	0.029	0.112	CbGbCtD
Methotrexate—SLCO1B3—Mycophenolate mofetil—psoriasis	0.0214	0.0828	CbGbCtD
Methotrexate—ABCC3—Cyclosporine—psoriasis	0.0183	0.0706	CbGbCtD
Methotrexate—ALB—Acitretin—psoriasis	0.0146	0.0564	CbGbCtD
Methotrexate—SLCO1B1—Mycophenolate mofetil—psoriasis	0.0125	0.0482	CbGbCtD
Methotrexate—ABCC1—Cyclosporine—psoriasis	0.0112	0.0434	CbGbCtD
Methotrexate—SLCO1A2—Prednisolone—psoriasis	0.0112	0.0432	CbGbCtD
Methotrexate—ABCC2—Mycophenolate mofetil—psoriasis	0.011	0.0424	CbGbCtD
Methotrexate—SLCO1A2—Hydrocortisone—psoriasis	0.0106	0.041	CbGbCtD
Methotrexate—SLCO1A2—Prednisone—psoriasis	0.0106	0.0408	CbGbCtD
Methotrexate—SLCO1A2—Cyclosporine—psoriasis	0.01	0.0387	CbGbCtD
Methotrexate—ABCG2—Mycophenolate mofetil—psoriasis	0.0099	0.0383	CbGbCtD
Methotrexate—SLCO1B1—Cyclosporine—psoriasis	0.00945	0.0365	CbGbCtD
Methotrexate—ABCC2—Cyclosporine—psoriasis	0.0083	0.0321	CbGbCtD
Methotrexate—ABCG2—Hydrocortisone—psoriasis	0.00795	0.0307	CbGbCtD
Methotrexate—ABCG2—Cyclosporine—psoriasis	0.00751	0.029	CbGbCtD
Methotrexate—ALB—Mycophenolate mofetil—psoriasis	0.00683	0.0264	CbGbCtD
Methotrexate—SLCO1A2—Dexamethasone—psoriasis	0.00659	0.0255	CbGbCtD
Methotrexate—SLC22A6—Cyclosporine—psoriasis	0.00607	0.0235	CbGbCtD
Methotrexate—ABCC2—Dexamethasone—psoriasis	0.00547	0.0211	CbGbCtD
Methotrexate—ALB—Prednisone—psoriasis	0.00546	0.0211	CbGbCtD
Methotrexate—ATIC—pes—psoriasis	0.00531	0.403	CbGeAlD
Methotrexate—ABCG2—Dexamethasone—psoriasis	0.00494	0.0191	CbGbCtD
Methotrexate—ABCB1—Mycophenolate mofetil—psoriasis	0.00357	0.0138	CbGbCtD
Methotrexate—ABCB1—Betamethasone—psoriasis	0.00306	0.0118	CbGbCtD
Methotrexate—ABCB1—Prednisolone—psoriasis	0.00302	0.0117	CbGbCtD
Methotrexate—ABCB1—Hydrocortisone—psoriasis	0.00287	0.0111	CbGbCtD
Methotrexate—ABCB1—Prednisone—psoriasis	0.00285	0.011	CbGbCtD
Methotrexate—ABCB1—Cyclosporine—psoriasis	0.00271	0.0105	CbGbCtD
Methotrexate—ABCB1—Dexamethasone—psoriasis	0.00178	0.00689	CbGbCtD
Methotrexate—ATIC—skin epidermis—psoriasis	0.00172	0.131	CbGeAlD
Methotrexate—GGH—skin of body—psoriasis	0.000628	0.0477	CbGeAlD
Methotrexate—FPGS—skin of body—psoriasis	0.000552	0.0419	CbGeAlD
Methotrexate—ATIC—skin of body—psoriasis	0.000534	0.0405	CbGeAlD
Methotrexate—SLC46A1—tendon—psoriasis	0.000486	0.0369	CbGeAlD
Methotrexate—GGH—tendon—psoriasis	0.000478	0.0363	CbGeAlD
Methotrexate—FPGS—tendon—psoriasis	0.00042	0.0319	CbGeAlD
Methotrexate—TYMS—skin of body—psoriasis	0.000362	0.0275	CbGeAlD
Methotrexate—PGD—skin of body—psoriasis	0.000345	0.0262	CbGeAlD
Methotrexate—SLCO3A1—tendon—psoriasis	0.000297	0.0226	CbGeAlD
Methotrexate—TYMS—tendon—psoriasis	0.000276	0.0209	CbGeAlD
Methotrexate—DHFR—tendon—psoriasis	0.000273	0.0207	CbGeAlD
Methotrexate—PGD—tendon—psoriasis	0.000262	0.0199	CbGeAlD
Methotrexate—SLC16A1—tendon—psoriasis	0.000245	0.0186	CbGeAlD
Methotrexate—TYMS—Vitamin A—Acitretin—psoriasis	0.000235	0.11	CbGdCrCtD
Methotrexate—AOX1—tendon—psoriasis	0.000231	0.0175	CbGeAlD
Methotrexate—ABCC10—tendon—psoriasis	0.000225	0.0171	CbGeAlD
Methotrexate—ABCC4—tendon—psoriasis	0.000187	0.0142	CbGeAlD
Methotrexate—ABCC2—tendon—psoriasis	0.000181	0.0137	CbGeAlD
Methotrexate—TYMS—Tretinoin—Acitretin—psoriasis	0.000164	0.0771	CbGdCrCtD
Methotrexate—TYMS—Isotretinoin—Acitretin—psoriasis	0.000164	0.0771	CbGdCrCtD
Methotrexate—TYMS—Alitretinoin—Acitretin—psoriasis	0.000164	0.0771	CbGdCrCtD
Methotrexate—ABCC1—tendon—psoriasis	0.000159	0.0121	CbGeAlD
Methotrexate—ATIC—Levonorgestrel—Hydrocortisone—psoriasis	5.35e-05	0.0251	CbGdCrCtD
Methotrexate—TYMS—Triamcinolone—Clobetasol propionate—psoriasis	4.91e-05	0.023	CbGdCrCtD
Methotrexate—TYMS—Fluticasone Propionate—Clobetasol propionate—psoriasis	4.78e-05	0.0224	CbGdCrCtD
Methotrexate—TYMS—Diflorasone—Clobetasol propionate—psoriasis	4.52e-05	0.0212	CbGdCrCtD
Methotrexate—TYMS—Clobetasol propionate—Fluocinonide—psoriasis	4.02e-05	0.0189	CbGdCrCtD
Methotrexate—TYMS—Clobetasol propionate—Beclomethasone—psoriasis	4.02e-05	0.0189	CbGdCrCtD
Methotrexate—TYMS—Flunisolide—Fluocinonide—psoriasis	3.97e-05	0.0186	CbGdCrCtD
Methotrexate—TYMS—Budesonide—Clobetasol propionate—psoriasis	3.96e-05	0.0186	CbGdCrCtD
Methotrexate—TYMS—Triamcinolone—Fluocinonide—psoriasis	3.93e-05	0.0184	CbGdCrCtD
Methotrexate—TYMS—Triamcinolone—Beclomethasone—psoriasis	3.93e-05	0.0184	CbGdCrCtD
Methotrexate—TYMS—Clobetasol propionate—Fluocinolone Acetonide—psoriasis	3.91e-05	0.0183	CbGdCrCtD
Methotrexate—TYMS—Flunisolide—Fluocinolone Acetonide—psoriasis	3.86e-05	0.0181	CbGdCrCtD
Methotrexate—TYMS—Fluticasone Propionate—Beclomethasone—psoriasis	3.83e-05	0.018	CbGdCrCtD
Methotrexate—TYMS—Fluticasone Propionate—Fluocinonide—psoriasis	3.83e-05	0.018	CbGdCrCtD
Methotrexate—TYMS—Triamcinolone—Fluocinolone Acetonide—psoriasis	3.82e-05	0.0179	CbGdCrCtD
Methotrexate—TYMS—Fluticasone Propionate—Fluocinolone Acetonide—psoriasis	3.72e-05	0.0175	CbGdCrCtD
Methotrexate—TYMS—Diflorasone—Fluocinonide—psoriasis	3.62e-05	0.017	CbGdCrCtD
Methotrexate—TYMS—Diflorasone—Beclomethasone—psoriasis	3.62e-05	0.017	CbGdCrCtD
Methotrexate—TYMS—Diflorasone—Fluocinolone Acetonide—psoriasis	3.52e-05	0.0165	CbGdCrCtD
Methotrexate—TYMS—Budesonide—Fluocinonide—psoriasis	3.18e-05	0.0149	CbGdCrCtD
Methotrexate—TYMS—Budesonide—Beclomethasone—psoriasis	3.18e-05	0.0149	CbGdCrCtD
Methotrexate—TYMS—Budesonide—Fluocinolone Acetonide—psoriasis	3.09e-05	0.0145	CbGdCrCtD
Methotrexate—SLC22A7—Transmembrane transport of small molecules—CARM1—psoriasis	2.71e-05	0.00108	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.71e-05	0.00108	CbGpPWpGaD
Methotrexate—SLCO1B3—Transmembrane transport of small molecules—CP—psoriasis	2.7e-05	0.00108	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—CYP2S1—psoriasis	2.69e-05	0.00108	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—NDUFA5—psoriasis	2.62e-05	0.00105	CbGpPWpGaD
Methotrexate—ALB—Folate Metabolism—ICAM1—psoriasis	2.62e-05	0.00104	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—CAT—psoriasis	2.61e-05	0.00104	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—HLA-A—psoriasis	2.59e-05	0.00104	CbGpPWpGaD
Methotrexate—TYMS—Retinoblastoma (RB) in Cancer—TP53—psoriasis	2.59e-05	0.00103	CbGpPWpGaD
Methotrexate—SLCO1B3—Transmembrane transport of small molecules—CARM1—psoriasis	2.58e-05	0.00103	CbGpPWpGaD
Methotrexate—PGD—Metabolism—CARM1—psoriasis	2.57e-05	0.00103	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—IL10—psoriasis	2.57e-05	0.00103	CbGpPWpGaD
Methotrexate—Dermatitis—Hydroxyurea—psoriasis	2.52e-05	0.000208	CcSEcCtD
Methotrexate—Myalgia—Hydrocortisone—psoriasis	2.51e-05	0.000207	CcSEcCtD
Methotrexate—Malaise—Triamcinolone—psoriasis	2.5e-05	0.000206	CcSEcCtD
Methotrexate—Headache—Hydroxyurea—psoriasis	2.5e-05	0.000206	CcSEcCtD
Methotrexate—ABCB1—Allograft Rejection—IL4—psoriasis	2.5e-05	0.000998	CbGpPWpGaD
Methotrexate—Vertigo—Triamcinolone—psoriasis	2.49e-05	0.000206	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	2.49e-05	0.000206	CcSEcCtD
Methotrexate—Discomfort—Hydrocortisone—psoriasis	2.48e-05	0.000204	CcSEcCtD
Methotrexate—SLCO1B3—Metabolism—CYP2S1—psoriasis	2.47e-05	0.000987	CbGpPWpGaD
Methotrexate—Hypotension—Mycophenolate mofetil—psoriasis	2.47e-05	0.000203	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Cyclosporine—psoriasis	2.47e-05	0.000203	CcSEcCtD
Methotrexate—Anaphylactic shock—Prednisolone—psoriasis	2.46e-05	0.000203	CcSEcCtD
Methotrexate—Insomnia—Cyclosporine—psoriasis	2.45e-05	0.000202	CcSEcCtD
Methotrexate—ALB—Vitamin B12 Metabolism—IFNG—psoriasis	2.45e-05	0.000977	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.45e-05	0.000976	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—HLA-B—psoriasis	2.44e-05	0.000976	CbGpPWpGaD
Methotrexate—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	2.44e-05	0.000974	CbGpPWpGaD
Methotrexate—ABCC3—Transmembrane transport of small molecules—CP—psoriasis	2.44e-05	0.000973	CbGpPWpGaD
Methotrexate—ABCG2—HIF-1-alpha transcription factor network—VEGFA—psoriasis	2.44e-05	0.000973	CbGpPWpGaD
Methotrexate—Paraesthesia—Cyclosporine—psoriasis	2.43e-05	0.0002	CcSEcCtD
Methotrexate—SLC19A1—Disease—APOE—psoriasis	2.42e-05	0.000967	CbGpPWpGaD
Methotrexate—Cough—Triamcinolone—psoriasis	2.42e-05	0.0002	CcSEcCtD
Methotrexate—Dyspnoea—Cyclosporine—psoriasis	2.41e-05	0.000199	CcSEcCtD
Methotrexate—Somnolence—Cyclosporine—psoriasis	2.41e-05	0.000198	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	2.4e-05	0.000198	CcSEcCtD
Methotrexate—Anaphylactic shock—Hydrocortisone—psoriasis	2.4e-05	0.000198	CcSEcCtD
Methotrexate—Convulsion—Triamcinolone—psoriasis	2.4e-05	0.000198	CcSEcCtD
Methotrexate—Asthenia—Mycophenolic acid—psoriasis	2.4e-05	0.000198	CcSEcCtD
Methotrexate—SLC22A8—Transmembrane transport of small molecules—CP—psoriasis	2.39e-05	0.000954	CbGpPWpGaD
Methotrexate—Infection—Hydrocortisone—psoriasis	2.39e-05	0.000197	CcSEcCtD
Methotrexate—Insomnia—Mycophenolate mofetil—psoriasis	2.39e-05	0.000197	CcSEcCtD
Methotrexate—Dyspepsia—Cyclosporine—psoriasis	2.38e-05	0.000196	CcSEcCtD
Methotrexate—Hyperhidrosis—Prednisolone—psoriasis	2.38e-05	0.000196	CcSEcCtD
Methotrexate—Nausea—Hydroxyurea—psoriasis	2.37e-05	0.000196	CcSEcCtD
Methotrexate—Paraesthesia—Mycophenolate mofetil—psoriasis	2.37e-05	0.000196	CcSEcCtD
Methotrexate—Pruritus—Mycophenolic acid—psoriasis	2.37e-05	0.000195	CcSEcCtD
Methotrexate—Myalgia—Triamcinolone—psoriasis	2.36e-05	0.000195	CcSEcCtD
Methotrexate—Nervous system disorder—Hydrocortisone—psoriasis	2.36e-05	0.000195	CcSEcCtD
Methotrexate—Eye disorder—Prednisone—psoriasis	2.35e-05	0.000194	CcSEcCtD
Methotrexate—Dyspnoea—Mycophenolate mofetil—psoriasis	2.35e-05	0.000194	CcSEcCtD
Methotrexate—Decreased appetite—Cyclosporine—psoriasis	2.35e-05	0.000194	CcSEcCtD
Methotrexate—Somnolence—Mycophenolate mofetil—psoriasis	2.35e-05	0.000194	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Cyclosporine—psoriasis	2.34e-05	0.000193	CcSEcCtD
Methotrexate—Skin disorder—Hydrocortisone—psoriasis	2.34e-05	0.000193	CcSEcCtD
Methotrexate—Ill-defined disorder—Dexamethasone—psoriasis	2.34e-05	0.000193	CcSEcCtD
Methotrexate—Ill-defined disorder—Betamethasone—psoriasis	2.34e-05	0.000193	CcSEcCtD
Methotrexate—Discomfort—Triamcinolone—psoriasis	2.33e-05	0.000193	CcSEcCtD
Methotrexate—Fatigue—Cyclosporine—psoriasis	2.33e-05	0.000192	CcSEcCtD
Methotrexate—ABCC3—Transmembrane transport of small molecules—CARM1—psoriasis	2.32e-05	0.000928	CbGpPWpGaD
Methotrexate—Hyperhidrosis—Hydrocortisone—psoriasis	2.32e-05	0.000192	CcSEcCtD
Methotrexate—Dyspepsia—Mycophenolate mofetil—psoriasis	2.32e-05	0.000192	CcSEcCtD
Methotrexate—Pain—Cyclosporine—psoriasis	2.31e-05	0.000191	CcSEcCtD
Methotrexate—Decreased appetite—Mycophenolate mofetil—psoriasis	2.29e-05	0.000189	CcSEcCtD
Methotrexate—Anorexia—Hydrocortisone—psoriasis	2.29e-05	0.000189	CcSEcCtD
Methotrexate—ABCC4—Transmembrane transport of small molecules—CP—psoriasis	2.29e-05	0.000915	CbGpPWpGaD
Methotrexate—Diarrhoea—Mycophenolic acid—psoriasis	2.29e-05	0.000189	CcSEcCtD
Methotrexate—Angiopathy—Prednisone—psoriasis	2.28e-05	0.000189	CcSEcCtD
Methotrexate—SLCO1A2—Metabolism—NDUFA5—psoriasis	2.28e-05	0.000912	CbGpPWpGaD
Methotrexate—SLC22A8—Transmembrane transport of small molecules—CARM1—psoriasis	2.28e-05	0.00091	CbGpPWpGaD
Methotrexate—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	2.28e-05	0.000188	CcSEcCtD
Methotrexate—Immune system disorder—Prednisone—psoriasis	2.27e-05	0.000188	CcSEcCtD
Methotrexate—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	2.27e-05	0.000908	CbGpPWpGaD
Methotrexate—Malaise—Dexamethasone—psoriasis	2.27e-05	0.000187	CcSEcCtD
Methotrexate—Malaise—Betamethasone—psoriasis	2.27e-05	0.000187	CcSEcCtD
Methotrexate—ABCB1—Allograft Rejection—HLA-A—psoriasis	2.26e-05	0.000904	CbGpPWpGaD
Methotrexate—Anaphylactic shock—Triamcinolone—psoriasis	2.26e-05	0.000187	CcSEcCtD
Methotrexate—Vertigo—Dexamethasone—psoriasis	2.26e-05	0.000187	CcSEcCtD
Methotrexate—Vertigo—Betamethasone—psoriasis	2.26e-05	0.000187	CcSEcCtD
Methotrexate—ALB—Selenium Micronutrient Network—CRP—psoriasis	2.26e-05	0.000903	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—NOS2—psoriasis	2.26e-05	0.000901	CbGpPWpGaD
Methotrexate—Pain—Mycophenolate mofetil—psoriasis	2.26e-05	0.000186	CcSEcCtD
Methotrexate—Infection—Triamcinolone—psoriasis	2.25e-05	0.000186	CcSEcCtD
Methotrexate—Hypotension—Hydrocortisone—psoriasis	2.25e-05	0.000185	CcSEcCtD
Methotrexate—ABCC3—Metabolism—CYP2S1—psoriasis	2.23e-05	0.00089	CbGpPWpGaD
Methotrexate—Feeling abnormal—Cyclosporine—psoriasis	2.23e-05	0.000184	CcSEcCtD
Methotrexate—Insomnia—Prednisolone—psoriasis	2.23e-05	0.000184	CcSEcCtD
Methotrexate—Alopecia—Prednisone—psoriasis	2.23e-05	0.000184	CcSEcCtD
Methotrexate—FPGS—Metabolism—CAT—psoriasis	2.22e-05	0.000886	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—CAT—psoriasis	2.22e-05	0.000886	CbGpPWpGaD
Methotrexate—Gastrointestinal pain—Cyclosporine—psoriasis	2.21e-05	0.000183	CcSEcCtD
Methotrexate—Dizziness—Mycophenolic acid—psoriasis	2.21e-05	0.000182	CcSEcCtD
Methotrexate—Paraesthesia—Prednisolone—psoriasis	2.21e-05	0.000182	CcSEcCtD
Methotrexate—Mental disorder—Prednisone—psoriasis	2.21e-05	0.000182	CcSEcCtD
Methotrexate—FPGS—Disease—HLA-A—psoriasis	2.21e-05	0.000881	CbGpPWpGaD
Methotrexate—Malnutrition—Prednisone—psoriasis	2.19e-05	0.000181	CcSEcCtD
Methotrexate—Erythema—Prednisone—psoriasis	2.19e-05	0.000181	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Hydrocortisone—psoriasis	2.19e-05	0.000181	CcSEcCtD
Methotrexate—Hyperhidrosis—Triamcinolone—psoriasis	2.19e-05	0.000181	CcSEcCtD
Methotrexate—ABCC4—Transmembrane transport of small molecules—CARM1—psoriasis	2.19e-05	0.000873	CbGpPWpGaD
Methotrexate—Convulsion—Betamethasone—psoriasis	2.18e-05	0.00018	CcSEcCtD
Methotrexate—Convulsion—Dexamethasone—psoriasis	2.18e-05	0.00018	CcSEcCtD
Methotrexate—Feeling abnormal—Mycophenolate mofetil—psoriasis	2.18e-05	0.000179	CcSEcCtD
Methotrexate—Insomnia—Hydrocortisone—psoriasis	2.17e-05	0.000179	CcSEcCtD
Methotrexate—Paraesthesia—Hydrocortisone—psoriasis	2.16e-05	0.000178	CcSEcCtD
Methotrexate—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	2.16e-05	0.000178	CcSEcCtD
Methotrexate—Urticaria—Cyclosporine—psoriasis	2.15e-05	0.000177	CcSEcCtD
Methotrexate—Myalgia—Betamethasone—psoriasis	2.14e-05	0.000177	CcSEcCtD
Methotrexate—Myalgia—Dexamethasone—psoriasis	2.14e-05	0.000177	CcSEcCtD
Methotrexate—Abdominal pain—Cyclosporine—psoriasis	2.14e-05	0.000176	CcSEcCtD
Methotrexate—Body temperature increased—Cyclosporine—psoriasis	2.14e-05	0.000176	CcSEcCtD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.13e-05	0.00085	CbGpPWpGaD
Methotrexate—Vomiting—Mycophenolic acid—psoriasis	2.13e-05	0.000175	CcSEcCtD
Methotrexate—SLCO1A2—Transmembrane transport of small molecules—CP—psoriasis	2.12e-05	0.000847	CbGpPWpGaD
Methotrexate—Discomfort—Dexamethasone—psoriasis	2.12e-05	0.000175	CcSEcCtD
Methotrexate—Discomfort—Betamethasone—psoriasis	2.12e-05	0.000175	CcSEcCtD
Methotrexate—Dyspepsia—Hydrocortisone—psoriasis	2.12e-05	0.000175	CcSEcCtD
Methotrexate—Rash—Mycophenolic acid—psoriasis	2.11e-05	0.000174	CcSEcCtD
Methotrexate—Dermatitis—Mycophenolic acid—psoriasis	2.11e-05	0.000174	CcSEcCtD
Methotrexate—Pain—Prednisolone—psoriasis	2.11e-05	0.000174	CcSEcCtD
Methotrexate—Urticaria—Mycophenolate mofetil—psoriasis	2.1e-05	0.000173	CcSEcCtD
Methotrexate—Headache—Mycophenolic acid—psoriasis	2.1e-05	0.000173	CcSEcCtD
Methotrexate—Decreased appetite—Hydrocortisone—psoriasis	2.09e-05	0.000172	CcSEcCtD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.09e-05	0.000834	CbGpPWpGaD
Methotrexate—Body temperature increased—Mycophenolate mofetil—psoriasis	2.09e-05	0.000172	CcSEcCtD
Methotrexate—Abdominal pain—Mycophenolate mofetil—psoriasis	2.09e-05	0.000172	CcSEcCtD
Methotrexate—DHFR—Cell Cycle, Mitotic—PCNA—psoriasis	2.08e-05	0.000831	CbGpPWpGaD
Methotrexate—ALB—Selenium Micronutrient Network—ICAM1—psoriasis	2.08e-05	0.00083	CbGpPWpGaD
Methotrexate—Gastrointestinal disorder—Hydrocortisone—psoriasis	2.08e-05	0.000171	CcSEcCtD
Methotrexate—Fatigue—Hydrocortisone—psoriasis	2.07e-05	0.000171	CcSEcCtD
Methotrexate—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	2.07e-05	0.000826	CbGpPWpGaD
Methotrexate—Vision blurred—Prednisone—psoriasis	2.07e-05	0.00017	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Triamcinolone—psoriasis	2.06e-05	0.00017	CcSEcCtD
Methotrexate—FPGS—Disease—APOE—psoriasis	2.06e-05	0.000822	CbGpPWpGaD
Methotrexate—Pain—Hydrocortisone—psoriasis	2.06e-05	0.00017	CcSEcCtD
Methotrexate—ABCC1—Metabolism—NDUFA5—psoriasis	2.05e-05	0.00082	CbGpPWpGaD
Methotrexate—Anaphylactic shock—Dexamethasone—psoriasis	2.05e-05	0.000169	CcSEcCtD
Methotrexate—Anaphylactic shock—Betamethasone—psoriasis	2.05e-05	0.000169	CcSEcCtD
Methotrexate—Insomnia—Triamcinolone—psoriasis	2.05e-05	0.000169	CcSEcCtD
Methotrexate—Infection—Dexamethasone—psoriasis	2.04e-05	0.000168	CcSEcCtD
Methotrexate—Infection—Betamethasone—psoriasis	2.04e-05	0.000168	CcSEcCtD
Methotrexate—ALB—SLC-mediated transmembrane transport—CP—psoriasis	2.04e-05	0.000815	CbGpPWpGaD
Methotrexate—ALB—Vitamin B12 Metabolism—NFKB1—psoriasis	2.04e-05	0.000813	CbGpPWpGaD
Methotrexate—Ill-defined disorder—Prednisone—psoriasis	2.03e-05	0.000168	CcSEcCtD
Methotrexate—Paraesthesia—Triamcinolone—psoriasis	2.03e-05	0.000168	CcSEcCtD
Methotrexate—Feeling abnormal—Prednisolone—psoriasis	2.03e-05	0.000167	CcSEcCtD
Methotrexate—SLC19A1—Metabolism—APOE—psoriasis	2.03e-05	0.00081	CbGpPWpGaD
Methotrexate—Anaemia—Prednisone—psoriasis	2.03e-05	0.000167	CcSEcCtD
Methotrexate—SLCO1A2—Transmembrane transport of small molecules—CARM1—psoriasis	2.02e-05	0.000808	CbGpPWpGaD
Methotrexate—Dyspnoea—Triamcinolone—psoriasis	2.02e-05	0.000167	CcSEcCtD
Methotrexate—Nervous system disorder—Dexamethasone—psoriasis	2.01e-05	0.000166	CcSEcCtD
Methotrexate—Nervous system disorder—Betamethasone—psoriasis	2.01e-05	0.000166	CcSEcCtD
Methotrexate—Thrombocytopenia—Betamethasone—psoriasis	2.01e-05	0.000166	CcSEcCtD
Methotrexate—Thrombocytopenia—Dexamethasone—psoriasis	2.01e-05	0.000166	CcSEcCtD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	2.01e-05	0.000803	CbGpPWpGaD
Methotrexate—TYMS—Circadian rythm related genes—JUN—psoriasis	2.01e-05	0.000801	CbGpPWpGaD
Methotrexate—SLC22A6—Transmembrane transport of small molecules—CP—psoriasis	1.99e-05	0.000796	CbGpPWpGaD
Methotrexate—Hypersensitivity—Cyclosporine—psoriasis	1.99e-05	0.000164	CcSEcCtD
Methotrexate—Dyspepsia—Triamcinolone—psoriasis	1.99e-05	0.000164	CcSEcCtD
Methotrexate—ALB—Folate Metabolism—IFNG—psoriasis	1.99e-05	0.000795	CbGpPWpGaD
Methotrexate—Nausea—Mycophenolic acid—psoriasis	1.99e-05	0.000164	CcSEcCtD
Methotrexate—Hyperhidrosis—Betamethasone—psoriasis	1.99e-05	0.000164	CcSEcCtD
Methotrexate—Hyperhidrosis—Dexamethasone—psoriasis	1.99e-05	0.000164	CcSEcCtD
Methotrexate—Feeling abnormal—Hydrocortisone—psoriasis	1.98e-05	0.000163	CcSEcCtD
Methotrexate—Malaise—Prednisone—psoriasis	1.98e-05	0.000163	CcSEcCtD
Methotrexate—Vertigo—Prednisone—psoriasis	1.97e-05	0.000162	CcSEcCtD
Methotrexate—Gastrointestinal pain—Hydrocortisone—psoriasis	1.97e-05	0.000162	CcSEcCtD
Methotrexate—Anorexia—Dexamethasone—psoriasis	1.96e-05	0.000162	CcSEcCtD
Methotrexate—Anorexia—Betamethasone—psoriasis	1.96e-05	0.000162	CcSEcCtD
Methotrexate—Urticaria—Prednisolone—psoriasis	1.96e-05	0.000161	CcSEcCtD
Methotrexate—SLCO1B1—Metabolism—NDUFA5—psoriasis	1.95e-05	0.00078	CbGpPWpGaD
Methotrexate—Fatigue—Triamcinolone—psoriasis	1.95e-05	0.000161	CcSEcCtD
Methotrexate—TYMS—Flunisolide—Hydrocortisone—psoriasis	1.95e-05	0.00914	CbGdCrCtD
Methotrexate—Hypersensitivity—Mycophenolate mofetil—psoriasis	1.94e-05	0.00016	CcSEcCtD
Methotrexate—SLCO1A2—Metabolism—CYP2S1—psoriasis	1.94e-05	0.000775	CbGpPWpGaD
Methotrexate—Asthenia—Cyclosporine—psoriasis	1.94e-05	0.00016	CcSEcCtD
Methotrexate—Pain—Triamcinolone—psoriasis	1.94e-05	0.00016	CcSEcCtD
Methotrexate—ABCC2—Transmembrane transport of small molecules—CP—psoriasis	1.93e-05	0.000771	CbGpPWpGaD
Methotrexate—TYMS—Triamcinolone—Hydrocortisone—psoriasis	1.93e-05	0.00905	CbGdCrCtD
Methotrexate—Hypotension—Betamethasone—psoriasis	1.92e-05	0.000158	CcSEcCtD
Methotrexate—Hypotension—Dexamethasone—psoriasis	1.92e-05	0.000158	CcSEcCtD
Methotrexate—FPGS—Disease—NOS2—psoriasis	1.92e-05	0.000766	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.92e-05	0.000765	CbGpPWpGaD
Methotrexate—Pruritus—Cyclosporine—psoriasis	1.91e-05	0.000158	CcSEcCtD
Methotrexate—Urticaria—Hydrocortisone—psoriasis	1.91e-05	0.000158	CcSEcCtD
Methotrexate—ABCC1—Transmembrane transport of small molecules—CP—psoriasis	1.91e-05	0.000762	CbGpPWpGaD
Methotrexate—SLC22A6—Transmembrane transport of small molecules—CARM1—psoriasis	1.9e-05	0.00076	CbGpPWpGaD
Methotrexate—Abdominal pain—Hydrocortisone—psoriasis	1.9e-05	0.000157	CcSEcCtD
Methotrexate—Body temperature increased—Hydrocortisone—psoriasis	1.9e-05	0.000157	CcSEcCtD
Methotrexate—Convulsion—Prednisone—psoriasis	1.9e-05	0.000157	CcSEcCtD
Methotrexate—Asthenia—Mycophenolate mofetil—psoriasis	1.89e-05	0.000156	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Betamethasone—psoriasis	1.87e-05	0.000154	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Dexamethasone—psoriasis	1.87e-05	0.000154	CcSEcCtD
Methotrexate—Pruritus—Mycophenolate mofetil—psoriasis	1.87e-05	0.000154	CcSEcCtD
Methotrexate—Arthralgia—Prednisone—psoriasis	1.87e-05	0.000154	CcSEcCtD
Methotrexate—Myalgia—Prednisone—psoriasis	1.87e-05	0.000154	CcSEcCtD
Methotrexate—Feeling abnormal—Triamcinolone—psoriasis	1.87e-05	0.000154	CcSEcCtD
Methotrexate—DHFR—Cell Cycle—PCNA—psoriasis	1.86e-05	0.000743	CbGpPWpGaD
Methotrexate—Insomnia—Betamethasone—psoriasis	1.86e-05	0.000153	CcSEcCtD
Methotrexate—Insomnia—Dexamethasone—psoriasis	1.86e-05	0.000153	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	1.85e-05	0.000153	CcSEcCtD
Methotrexate—Diarrhoea—Cyclosporine—psoriasis	1.85e-05	0.000153	CcSEcCtD
Methotrexate—SLC19A1—Disease—TYK2—psoriasis	1.85e-05	0.000738	CbGpPWpGaD
Methotrexate—Paraesthesia—Betamethasone—psoriasis	1.84e-05	0.000152	CcSEcCtD
Methotrexate—Paraesthesia—Dexamethasone—psoriasis	1.84e-05	0.000152	CcSEcCtD
Methotrexate—Discomfort—Prednisone—psoriasis	1.84e-05	0.000152	CcSEcCtD
Methotrexate—ABCC2—Transmembrane transport of small molecules—CARM1—psoriasis	1.84e-05	0.000736	CbGpPWpGaD
Methotrexate—TYMS—Clobetasol propionate—Betamethasone—psoriasis	1.83e-05	0.0086	CbGdCrCtD
Methotrexate—TYMS—Clobetasol propionate—Dexamethasone—psoriasis	1.83e-05	0.0086	CbGdCrCtD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.82e-05	0.000728	CbGpPWpGaD
Methotrexate—ABCC1—Transmembrane transport of small molecules—CARM1—psoriasis	1.82e-05	0.000727	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.82e-05	0.000727	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle, Mitotic—PCNA—psoriasis	1.82e-05	0.000725	CbGpPWpGaD
Methotrexate—SLCO1B1—Transmembrane transport of small molecules—CP—psoriasis	1.81e-05	0.000724	CbGpPWpGaD
Methotrexate—Hypersensitivity—Prednisolone—psoriasis	1.81e-05	0.00015	CcSEcCtD
Methotrexate—TYMS—Flunisolide—Dexamethasone—psoriasis	1.81e-05	0.00849	CbGdCrCtD
Methotrexate—TYMS—Flunisolide—Betamethasone—psoriasis	1.81e-05	0.00849	CbGdCrCtD
Methotrexate—Dyspepsia—Betamethasone—psoriasis	1.81e-05	0.000149	CcSEcCtD
Methotrexate—Dyspepsia—Dexamethasone—psoriasis	1.81e-05	0.000149	CcSEcCtD
Methotrexate—ABCG2—Metabolism—NDUFA5—psoriasis	1.81e-05	0.000722	CbGpPWpGaD
Methotrexate—Diarrhoea—Mycophenolate mofetil—psoriasis	1.81e-05	0.000149	CcSEcCtD
Methotrexate—Urticaria—Triamcinolone—psoriasis	1.8e-05	0.000148	CcSEcCtD
Methotrexate—TYMS—Clobetasol propionate—Triamcinolone—psoriasis	1.79e-05	0.0084	CbGdCrCtD
Methotrexate—TYMS—Triamcinolone—Dexamethasone—psoriasis	1.79e-05	0.0084	CbGdCrCtD
Methotrexate—TYMS—Triamcinolone—Betamethasone—psoriasis	1.79e-05	0.0084	CbGdCrCtD
Methotrexate—Body temperature increased—Triamcinolone—psoriasis	1.79e-05	0.000148	CcSEcCtD
Methotrexate—Dizziness—Cyclosporine—psoriasis	1.79e-05	0.000148	CcSEcCtD
Methotrexate—Anaphylactic shock—Prednisone—psoriasis	1.79e-05	0.000148	CcSEcCtD
Methotrexate—Decreased appetite—Dexamethasone—psoriasis	1.79e-05	0.000147	CcSEcCtD
Methotrexate—Decreased appetite—Betamethasone—psoriasis	1.79e-05	0.000147	CcSEcCtD
Methotrexate—Infection—Prednisone—psoriasis	1.78e-05	0.000147	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Betamethasone—psoriasis	1.77e-05	0.000146	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Dexamethasone—psoriasis	1.77e-05	0.000146	CcSEcCtD
Methotrexate—Hypersensitivity—Hydrocortisone—psoriasis	1.77e-05	0.000146	CcSEcCtD
Methotrexate—Fatigue—Dexamethasone—psoriasis	1.77e-05	0.000146	CcSEcCtD
Methotrexate—Fatigue—Betamethasone—psoriasis	1.77e-05	0.000146	CcSEcCtD
Methotrexate—TYMS—Flunisolide—Triamcinolone—psoriasis	1.77e-05	0.00829	CbGdCrCtD
Methotrexate—SLC19A1—Metabolism—PPARG—psoriasis	1.77e-05	0.000705	CbGpPWpGaD
Methotrexate—Pain—Betamethasone—psoriasis	1.76e-05	0.000145	CcSEcCtD
Methotrexate—Pain—Dexamethasone—psoriasis	1.76e-05	0.000145	CcSEcCtD
Methotrexate—Nervous system disorder—Prednisone—psoriasis	1.75e-05	0.000145	CcSEcCtD
Methotrexate—ABCC1—Metabolism—CYP2S1—psoriasis	1.75e-05	0.000698	CbGpPWpGaD
Methotrexate—TYMS—Fluticasone Propionate—Betamethasone—psoriasis	1.75e-05	0.00819	CbGdCrCtD
Methotrexate—TYMS—Fluticasone Propionate—Dexamethasone—psoriasis	1.75e-05	0.00819	CbGdCrCtD
Methotrexate—Dizziness—Mycophenolate mofetil—psoriasis	1.75e-05	0.000144	CcSEcCtD
Methotrexate—Skin disorder—Prednisone—psoriasis	1.74e-05	0.000143	CcSEcCtD
Methotrexate—SLCO1B1—Transmembrane transport of small molecules—CARM1—psoriasis	1.73e-05	0.000691	CbGpPWpGaD
Methotrexate—Hyperhidrosis—Prednisone—psoriasis	1.73e-05	0.000143	CcSEcCtD
Methotrexate—SLC46A1—Metabolism—CAT—psoriasis	1.73e-05	0.00069	CbGpPWpGaD
Methotrexate—Asthenia—Hydrocortisone—psoriasis	1.73e-05	0.000142	CcSEcCtD
Methotrexate—FPGS—Metabolism—APOE—psoriasis	1.72e-05	0.000689	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—APOE—psoriasis	1.72e-05	0.000689	CbGpPWpGaD
Methotrexate—Vomiting—Cyclosporine—psoriasis	1.72e-05	0.000142	CcSEcCtD
Methotrexate—SLC46A1—Disease—HLA-A—psoriasis	1.72e-05	0.000686	CbGpPWpGaD
Methotrexate—TYMS—Fluticasone Propionate—Triamcinolone—psoriasis	1.71e-05	0.00801	CbGdCrCtD
Methotrexate—Rash—Cyclosporine—psoriasis	1.71e-05	0.000141	CcSEcCtD
Methotrexate—Anorexia—Prednisone—psoriasis	1.71e-05	0.000141	CcSEcCtD
Methotrexate—Dermatitis—Cyclosporine—psoriasis	1.7e-05	0.000141	CcSEcCtD
Methotrexate—Pruritus—Hydrocortisone—psoriasis	1.7e-05	0.00014	CcSEcCtD
Methotrexate—TYMS—Clobetasol propionate—Prednisone—psoriasis	1.7e-05	0.00798	CbGdCrCtD
Methotrexate—MTHFR—Metabolism—CARM1—psoriasis	1.7e-05	0.000677	CbGpPWpGaD
Methotrexate—Headache—Cyclosporine—psoriasis	1.7e-05	0.00014	CcSEcCtD
Methotrexate—Feeling abnormal—Dexamethasone—psoriasis	1.69e-05	0.00014	CcSEcCtD
Methotrexate—Feeling abnormal—Betamethasone—psoriasis	1.69e-05	0.00014	CcSEcCtD
Methotrexate—ABCG2—Transmembrane transport of small molecules—CP—psoriasis	1.68e-05	0.000671	CbGpPWpGaD
Methotrexate—Gastrointestinal pain—Betamethasone—psoriasis	1.68e-05	0.000139	CcSEcCtD
Methotrexate—Gastrointestinal pain—Dexamethasone—psoriasis	1.68e-05	0.000139	CcSEcCtD
Methotrexate—Vomiting—Mycophenolate mofetil—psoriasis	1.68e-05	0.000138	CcSEcCtD
Methotrexate—TYMS—Flunisolide—Prednisone—psoriasis	1.68e-05	0.00787	CbGdCrCtD
Methotrexate—SLC19A1—Disease—CD4—psoriasis	1.67e-05	0.000668	CbGpPWpGaD
Methotrexate—Hypersensitivity—Triamcinolone—psoriasis	1.67e-05	0.000138	CcSEcCtD
Methotrexate—Rash—Mycophenolate mofetil—psoriasis	1.66e-05	0.000137	CcSEcCtD
Methotrexate—Dermatitis—Mycophenolate mofetil—psoriasis	1.66e-05	0.000137	CcSEcCtD
Methotrexate—TYMS—Triamcinolone—Prednisone—psoriasis	1.66e-05	0.00779	CbGdCrCtD
Methotrexate—SLCO1B1—Metabolism—CYP2S1—psoriasis	1.66e-05	0.000663	CbGpPWpGaD
Methotrexate—TYMS—Clobetasol propionate—Prednisolone—psoriasis	1.66e-05	0.00779	CbGdCrCtD
Methotrexate—AOX1—Metabolism—CARM1—psoriasis	1.66e-05	0.000662	CbGpPWpGaD
Methotrexate—ALB—Folate Metabolism—NFKB1—psoriasis	1.66e-05	0.000661	CbGpPWpGaD
Methotrexate—Headache—Mycophenolate mofetil—psoriasis	1.65e-05	0.000136	CcSEcCtD
Methotrexate—TYMS—Diflorasone—Betamethasone—psoriasis	1.65e-05	0.00774	CbGdCrCtD
Methotrexate—TYMS—Diflorasone—Dexamethasone—psoriasis	1.65e-05	0.00774	CbGdCrCtD
Methotrexate—Diarrhoea—Hydrocortisone—psoriasis	1.65e-05	0.000136	CcSEcCtD
Methotrexate—TYMS—Flunisolide—Prednisolone—psoriasis	1.64e-05	0.00768	CbGdCrCtD
Methotrexate—Urticaria—Betamethasone—psoriasis	1.63e-05	0.000135	CcSEcCtD
Methotrexate—Urticaria—Dexamethasone—psoriasis	1.63e-05	0.000135	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Prednisone—psoriasis	1.63e-05	0.000134	CcSEcCtD
Methotrexate—Dizziness—Prednisolone—psoriasis	1.63e-05	0.000134	CcSEcCtD
Methotrexate—Asthenia—Triamcinolone—psoriasis	1.62e-05	0.000134	CcSEcCtD
Methotrexate—Abdominal pain—Betamethasone—psoriasis	1.62e-05	0.000134	CcSEcCtD
Methotrexate—Abdominal pain—Dexamethasone—psoriasis	1.62e-05	0.000134	CcSEcCtD
Methotrexate—Body temperature increased—Dexamethasone—psoriasis	1.62e-05	0.000134	CcSEcCtD
Methotrexate—Body temperature increased—Betamethasone—psoriasis	1.62e-05	0.000134	CcSEcCtD
Methotrexate—TYMS—Cell Cycle—PCNA—psoriasis	1.62e-05	0.000648	CbGpPWpGaD
Methotrexate—TYMS—Triamcinolone—Prednisolone—psoriasis	1.62e-05	0.00761	CbGdCrCtD
Methotrexate—Insomnia—Prednisone—psoriasis	1.62e-05	0.000134	CcSEcCtD
Methotrexate—TYMS—Diflorasone—Triamcinolone—psoriasis	1.61e-05	0.00757	CbGdCrCtD
Methotrexate—Nausea—Cyclosporine—psoriasis	1.61e-05	0.000133	CcSEcCtD
Methotrexate—Paraesthesia—Prednisone—psoriasis	1.61e-05	0.000133	CcSEcCtD
Methotrexate—SLC46A1—Disease—APOE—psoriasis	1.6e-05	0.000641	CbGpPWpGaD
Methotrexate—ABCG2—Transmembrane transport of small molecules—CARM1—psoriasis	1.6e-05	0.00064	CbGpPWpGaD
Methotrexate—Pruritus—Triamcinolone—psoriasis	1.6e-05	0.000132	CcSEcCtD
Methotrexate—Dizziness—Hydrocortisone—psoriasis	1.59e-05	0.000131	CcSEcCtD
Methotrexate—ALB—Vitamin B12 Metabolism—TNF—psoriasis	1.58e-05	0.000632	CbGpPWpGaD
Methotrexate—PGD—Metabolism—CAT—psoriasis	1.58e-05	0.000632	CbGpPWpGaD
Methotrexate—ALB—Selenium Micronutrient Network—IFNG—psoriasis	1.58e-05	0.000631	CbGpPWpGaD
Methotrexate—Dyspepsia—Prednisone—psoriasis	1.57e-05	0.00013	CcSEcCtD
Methotrexate—PGD—Disease—HLA-A—psoriasis	1.57e-05	0.000628	CbGpPWpGaD
Methotrexate—FPGS—Disease—TYK2—psoriasis	1.57e-05	0.000628	CbGpPWpGaD
Methotrexate—Nausea—Mycophenolate mofetil—psoriasis	1.57e-05	0.000129	CcSEcCtD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.56e-05	0.000624	CbGpPWpGaD
Methotrexate—TYMS—Budesonide—Hydrocortisone—psoriasis	1.56e-05	0.00731	CbGdCrCtD
Methotrexate—Decreased appetite—Prednisone—psoriasis	1.56e-05	0.000128	CcSEcCtD
Methotrexate—Rash—Prednisolone—psoriasis	1.55e-05	0.000128	CcSEcCtD
Methotrexate—Dermatitis—Prednisolone—psoriasis	1.55e-05	0.000128	CcSEcCtD
Methotrexate—Fatigue—Prednisone—psoriasis	1.54e-05	0.000127	CcSEcCtD
Methotrexate—Headache—Prednisolone—psoriasis	1.54e-05	0.000127	CcSEcCtD
Methotrexate—ABCG2—Metabolism—CYP2S1—psoriasis	1.54e-05	0.000614	CbGpPWpGaD
Methotrexate—TYMS—Diflorasone—Prednisone—psoriasis	1.53e-05	0.00718	CbGdCrCtD
Methotrexate—Vomiting—Hydrocortisone—psoriasis	1.53e-05	0.000126	CcSEcCtD
Methotrexate—Rash—Hydrocortisone—psoriasis	1.52e-05	0.000125	CcSEcCtD
Methotrexate—Dermatitis—Hydrocortisone—psoriasis	1.51e-05	0.000125	CcSEcCtD
Methotrexate—ABCB1—Allograft Rejection—IFNG—psoriasis	1.51e-05	0.000603	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—NOS2—psoriasis	1.51e-05	0.000602	CbGpPWpGaD
Methotrexate—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	1.51e-05	0.000602	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—CARM1—psoriasis	1.51e-05	0.000602	CbGpPWpGaD
Methotrexate—Headache—Hydrocortisone—psoriasis	1.51e-05	0.000124	CcSEcCtD
Methotrexate—ATIC—Metabolism—PPARG—psoriasis	1.5e-05	0.0006	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—PPARG—psoriasis	1.5e-05	0.0006	CbGpPWpGaD
Methotrexate—Dizziness—Triamcinolone—psoriasis	1.5e-05	0.000124	CcSEcCtD
Methotrexate—SLC46A1—Disease—NOS2—psoriasis	1.5e-05	0.000597	CbGpPWpGaD
Methotrexate—TYMS—Diflorasone—Prednisolone—psoriasis	1.49e-05	0.00701	CbGdCrCtD
Methotrexate—TYMS—Danazol—Hydrocortisone—psoriasis	1.49e-05	0.00701	CbGdCrCtD
Methotrexate—Feeling abnormal—Prednisone—psoriasis	1.47e-05	0.000122	CcSEcCtD
Methotrexate—Asthenia—Dexamethasone—psoriasis	1.47e-05	0.000122	CcSEcCtD
Methotrexate—Asthenia—Betamethasone—psoriasis	1.47e-05	0.000122	CcSEcCtD
Methotrexate—PGD—Disease—APOE—psoriasis	1.47e-05	0.000586	CbGpPWpGaD
Methotrexate—Gastrointestinal pain—Prednisone—psoriasis	1.46e-05	0.000121	CcSEcCtD
Methotrexate—Nausea—Prednisolone—psoriasis	1.46e-05	0.000121	CcSEcCtD
Methotrexate—Pruritus—Dexamethasone—psoriasis	1.45e-05	0.00012	CcSEcCtD
Methotrexate—Pruritus—Betamethasone—psoriasis	1.45e-05	0.00012	CcSEcCtD
Methotrexate—TYMS—Budesonide—Betamethasone—psoriasis	1.45e-05	0.00679	CbGdCrCtD
Methotrexate—TYMS—Budesonide—Dexamethasone—psoriasis	1.45e-05	0.00679	CbGdCrCtD
Methotrexate—Vomiting—Triamcinolone—psoriasis	1.44e-05	0.000119	CcSEcCtD
Methotrexate—Nausea—Hydrocortisone—psoriasis	1.43e-05	0.000118	CcSEcCtD
Methotrexate—Rash—Triamcinolone—psoriasis	1.43e-05	0.000118	CcSEcCtD
Methotrexate—Dermatitis—Triamcinolone—psoriasis	1.43e-05	0.000118	CcSEcCtD
Methotrexate—FPGS—Disease—CD4—psoriasis	1.42e-05	0.000568	CbGpPWpGaD
Methotrexate—Urticaria—Prednisone—psoriasis	1.42e-05	0.000117	CcSEcCtD
Methotrexate—Headache—Triamcinolone—psoriasis	1.42e-05	0.000117	CcSEcCtD
Methotrexate—Body temperature increased—Prednisone—psoriasis	1.41e-05	0.000117	CcSEcCtD
Methotrexate—Abdominal pain—Prednisone—psoriasis	1.41e-05	0.000117	CcSEcCtD
Methotrexate—TYMS—Budesonide—Triamcinolone—psoriasis	1.41e-05	0.00663	CbGdCrCtD
Methotrexate—Diarrhoea—Dexamethasone—psoriasis	1.41e-05	0.000116	CcSEcCtD
Methotrexate—Diarrhoea—Betamethasone—psoriasis	1.41e-05	0.000116	CcSEcCtD
Methotrexate—ABCB1—Allograft Rejection—CXCL8—psoriasis	1.4e-05	0.000561	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.38e-05	0.00055	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—CARM1—psoriasis	1.37e-05	0.000548	CbGpPWpGaD
Methotrexate—PGD—Disease—NOS2—psoriasis	1.37e-05	0.000546	CbGpPWpGaD
Methotrexate—Dizziness—Betamethasone—psoriasis	1.36e-05	0.000112	CcSEcCtD
Methotrexate—Dizziness—Dexamethasone—psoriasis	1.36e-05	0.000112	CcSEcCtD
Methotrexate—Nausea—Triamcinolone—psoriasis	1.34e-05	0.000111	CcSEcCtD
Methotrexate—SLC46A1—Metabolism—APOE—psoriasis	1.34e-05	0.000536	CbGpPWpGaD
Methotrexate—TYMS—Budesonide—Prednisone—psoriasis	1.34e-05	0.0063	CbGdCrCtD
Methotrexate—TYMS—Circadian rythm related genes—TP53—psoriasis	1.32e-05	0.000528	CbGpPWpGaD
Methotrexate—Hypersensitivity—Prednisone—psoriasis	1.32e-05	0.000109	CcSEcCtD
Methotrexate—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	1.32e-05	0.000526	CbGpPWpGaD
Methotrexate—ALB—Selenium Micronutrient Network—NFKB1—psoriasis	1.32e-05	0.000525	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—CARM1—psoriasis	1.32e-05	0.000525	CbGpPWpGaD
Methotrexate—TYMS—Budesonide—Prednisolone—psoriasis	1.31e-05	0.00615	CbGdCrCtD
Methotrexate—Vomiting—Dexamethasone—psoriasis	1.31e-05	0.000108	CcSEcCtD
Methotrexate—Vomiting—Betamethasone—psoriasis	1.31e-05	0.000108	CcSEcCtD
Methotrexate—Rash—Dexamethasone—psoriasis	1.3e-05	0.000107	CcSEcCtD
Methotrexate—Rash—Betamethasone—psoriasis	1.3e-05	0.000107	CcSEcCtD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.3e-05	0.000517	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—STAT3—psoriasis	1.29e-05	0.000517	CbGpPWpGaD
Methotrexate—Dermatitis—Betamethasone—psoriasis	1.29e-05	0.000107	CcSEcCtD
Methotrexate—Dermatitis—Dexamethasone—psoriasis	1.29e-05	0.000107	CcSEcCtD
Methotrexate—ALB—Platelet degranulation—VEGFA—psoriasis	1.29e-05	0.000515	CbGpPWpGaD
Methotrexate—ALB—Folate Metabolism—TNF—psoriasis	1.29e-05	0.000514	CbGpPWpGaD
Methotrexate—Headache—Betamethasone—psoriasis	1.29e-05	0.000106	CcSEcCtD
Methotrexate—Headache—Dexamethasone—psoriasis	1.29e-05	0.000106	CcSEcCtD
Methotrexate—TYMS—Danazol—Prednisone—psoriasis	1.29e-05	0.00603	CbGdCrCtD
Methotrexate—Asthenia—Prednisone—psoriasis	1.28e-05	0.000106	CcSEcCtD
Methotrexate—ALB—Vitamin B12 Metabolism—IL6—psoriasis	1.28e-05	0.00051	CbGpPWpGaD
Methotrexate—Pruritus—Prednisone—psoriasis	1.27e-05	0.000104	CcSEcCtD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—VEGFA—psoriasis	1.26e-05	0.000504	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—ITGAL—psoriasis	1.24e-05	0.000495	CbGpPWpGaD
Methotrexate—PGD—Metabolism—APOE—psoriasis	1.23e-05	0.000491	CbGpPWpGaD
Methotrexate—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	1.23e-05	0.00049	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—TYK2—psoriasis	1.22e-05	0.000489	CbGpPWpGaD
Methotrexate—Diarrhoea—Prednisone—psoriasis	1.22e-05	0.000101	CcSEcCtD
Methotrexate—Nausea—Dexamethasone—psoriasis	1.22e-05	0.000101	CcSEcCtD
Methotrexate—Nausea—Betamethasone—psoriasis	1.22e-05	0.000101	CcSEcCtD
Methotrexate—TYMS—Circadian rythm related genes—IL6—psoriasis	1.21e-05	0.000484	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—CARM1—psoriasis	1.21e-05	0.000482	CbGpPWpGaD
Methotrexate—Dizziness—Prednisone—psoriasis	1.18e-05	9.76e-05	CcSEcCtD
Methotrexate—SLC46A1—Metabolism—PPARG—psoriasis	1.17e-05	0.000467	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.17e-05	0.000467	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	1.16e-05	0.000462	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—VEGFA—psoriasis	1.14e-05	0.000455	CbGpPWpGaD
Methotrexate—Vomiting—Prednisone—psoriasis	1.14e-05	9.39e-05	CcSEcCtD
Methotrexate—ALB—Folate Metabolism—TP53—psoriasis	1.14e-05	0.000454	CbGpPWpGaD
Methotrexate—Rash—Prednisone—psoriasis	1.13e-05	9.31e-05	CcSEcCtD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.13e-05	0.00045	CbGpPWpGaD
Methotrexate—Dermatitis—Prednisone—psoriasis	1.13e-05	9.3e-05	CcSEcCtD
Methotrexate—ABCC4—Hemostasis—NOS2—psoriasis	1.12e-05	0.000449	CbGpPWpGaD
Methotrexate—Headache—Prednisone—psoriasis	1.12e-05	9.25e-05	CcSEcCtD
Methotrexate—PGD—Disease—TYK2—psoriasis	1.12e-05	0.000447	CbGpPWpGaD
Methotrexate—ALB—Metabolism—NDUFA5—psoriasis	1.12e-05	0.000445	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—CD4—psoriasis	1.11e-05	0.000442	CbGpPWpGaD
Methotrexate—FPGS—Disease—STAT3—psoriasis	1.1e-05	0.000439	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—CARM1—psoriasis	1.09e-05	0.000435	CbGpPWpGaD
Methotrexate—TYMS—Levonorgestrel—Hydrocortisone—psoriasis	1.07e-05	0.00502	CbGdCrCtD
Methotrexate—PGD—Metabolism—PPARG—psoriasis	1.07e-05	0.000427	CbGpPWpGaD
Methotrexate—Nausea—Prednisone—psoriasis	1.06e-05	8.77e-05	CcSEcCtD
Methotrexate—MTHFR—Metabolism—CAT—psoriasis	1.04e-05	0.000417	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.04e-05	0.000415	CbGpPWpGaD
Methotrexate—ALB—Folate Metabolism—IL6—psoriasis	1.04e-05	0.000415	CbGpPWpGaD
Methotrexate—MTHFR—Disease—HLA-A—psoriasis	1.04e-05	0.000414	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—CP—psoriasis	1.04e-05	0.000414	CbGpPWpGaD
Methotrexate—ALB—Selenium Micronutrient Network—TNF—psoriasis	1.02e-05	0.000409	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—CAT—psoriasis	1.02e-05	0.000407	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.02e-05	0.000406	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.02e-05	0.000406	CbGpPWpGaD
Methotrexate—PGD—Disease—CD4—psoriasis	1.01e-05	0.000404	CbGpPWpGaD
Methotrexate—AOX1—Disease—HLA-A—psoriasis	1.01e-05	0.000404	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—CARM1—psoriasis	9.89e-06	0.000395	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—TNF—psoriasis	9.78e-06	0.00039	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—NDUFA5—psoriasis	9.78e-06	0.00039	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	9.72e-06	0.000388	CbGpPWpGaD
Methotrexate—MTHFR—Disease—APOE—psoriasis	9.68e-06	0.000387	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP2S1—psoriasis	9.49e-06	0.000379	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—CARM1—psoriasis	9.48e-06	0.000379	CbGpPWpGaD
Methotrexate—AOX1—Disease—APOE—psoriasis	9.46e-06	0.000378	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—CAT—psoriasis	9.27e-06	0.00037	CbGpPWpGaD
Methotrexate—DHFR—Disease—HLA-A—psoriasis	9.22e-06	0.000368	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.16e-06	0.000366	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	9.09e-06	0.000363	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—IL6—psoriasis	9.04e-06	0.000361	CbGpPWpGaD
Methotrexate—MTHFR—Disease—NOS2—psoriasis	9.02e-06	0.00036	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.86e-06	0.000354	CbGpPWpGaD
Methotrexate—AOX1—Disease—NOS2—psoriasis	8.81e-06	0.000352	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—VEGFA—psoriasis	8.74e-06	0.000349	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.7e-06	0.000347	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	8.67e-06	0.000346	CbGpPWpGaD
Methotrexate—DHFR—Disease—APOE—psoriasis	8.6e-06	0.000343	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—STAT3—psoriasis	8.58e-06	0.000342	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CARM1—psoriasis	8.53e-06	0.000341	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—CAT—psoriasis	8.45e-06	0.000337	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP2S1—psoriasis	8.31e-06	0.000332	CbGpPWpGaD
Methotrexate—ALB—Selenium Micronutrient Network—IL6—psoriasis	8.26e-06	0.00033	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CARM1—psoriasis	8.11e-06	0.000324	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—APOE—psoriasis	8.11e-06	0.000324	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—CAT—psoriasis	8.09e-06	0.000323	CbGpPWpGaD
Methotrexate—DHFR—Disease—NOS2—psoriasis	8.02e-06	0.00032	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.98e-06	0.000318	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—APOE—psoriasis	7.92e-06	0.000316	CbGpPWpGaD
Methotrexate—PGD—Disease—STAT3—psoriasis	7.84e-06	0.000313	CbGpPWpGaD
Methotrexate—FPGS—Disease—IL6—psoriasis	7.69e-06	0.000307	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.58e-06	0.000303	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CARM1—psoriasis	7.51e-06	0.0003	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—CAT—psoriasis	7.42e-06	0.000296	CbGpPWpGaD
Methotrexate—MTHFR—Disease—TYK2—psoriasis	7.39e-06	0.000295	CbGpPWpGaD
Methotrexate—AOX1—Disease—TYK2—psoriasis	7.22e-06	0.000288	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—APOE—psoriasis	7.21e-06	0.000288	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PPARG—psoriasis	7.06e-06	0.000282	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PPARG—psoriasis	6.9e-06	0.000275	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—TP53—psoriasis	6.84e-06	0.000273	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—CAT—psoriasis	6.7e-06	0.000267	CbGpPWpGaD
Methotrexate—MTHFR—Disease—CD4—psoriasis	6.68e-06	0.000267	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—TP53—psoriasis	6.6e-06	0.000264	CbGpPWpGaD
Methotrexate—DHFR—Disease—TYK2—psoriasis	6.57e-06	0.000262	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—APOE—psoriasis	6.56e-06	0.000262	CbGpPWpGaD
Methotrexate—AOX1—Disease—CD4—psoriasis	6.53e-06	0.000261	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—VEGFA—psoriasis	6.51e-06	0.00026	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	6.44e-06	0.000257	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—APOE—psoriasis	6.29e-06	0.000251	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PPARG—psoriasis	6.28e-06	0.000251	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	6.2e-06	0.000248	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—IL6—psoriasis	5.99e-06	0.000239	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—TP53—psoriasis	5.97e-06	0.000238	CbGpPWpGaD
Methotrexate—DHFR—Disease—CD4—psoriasis	5.94e-06	0.000237	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—CAT—psoriasis	5.83e-06	0.000233	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—APOE—psoriasis	5.77e-06	0.00023	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—VEGFA—psoriasis	5.72e-06	0.000228	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PPARG—psoriasis	5.72e-06	0.000228	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	5.63e-06	0.000225	CbGpPWpGaD
Methotrexate—PGD—Disease—IL6—psoriasis	5.48e-06	0.000219	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PPARG—psoriasis	5.48e-06	0.000219	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CAT—psoriasis	5.25e-06	0.00021	CbGpPWpGaD
Methotrexate—ABCC1—Disease—HLA-A—psoriasis	5.22e-06	0.000208	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—APOE—psoriasis	5.2e-06	0.000208	CbGpPWpGaD
Methotrexate—MTHFR—Disease—STAT3—psoriasis	5.17e-06	0.000207	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—NOS2—psoriasis	5.09e-06	0.000203	CbGpPWpGaD
Methotrexate—AOX1—Disease—STAT3—psoriasis	5.05e-06	0.000202	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PPARG—psoriasis	5.02e-06	0.000201	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CAT—psoriasis	4.99e-06	0.000199	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—APOE—psoriasis	4.97e-06	0.000198	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—TP53—psoriasis	4.92e-06	0.000196	CbGpPWpGaD
Methotrexate—ABCC1—Disease—APOE—psoriasis	4.87e-06	0.000194	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	4.83e-06	0.000193	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CARM1—psoriasis	4.63e-06	0.000185	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CAT—psoriasis	4.62e-06	0.000184	CbGpPWpGaD
Methotrexate—DHFR—Disease—STAT3—psoriasis	4.6e-06	0.000184	CbGpPWpGaD
Methotrexate—ABCC1—Disease—NOS2—psoriasis	4.54e-06	0.000181	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PPARG—psoriasis	4.53e-06	0.000181	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—APOE—psoriasis	4.53e-06	0.000181	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.33e-06	0.000173	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	4.25e-06	0.00017	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—APOE—psoriasis	4.08e-06	0.000163	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CARM1—psoriasis	4.06e-06	0.000162	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PPARG—psoriasis	3.95e-06	0.000158	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—APOE—psoriasis	3.88e-06	0.000155	CbGpPWpGaD
Methotrexate—ABCC1—Disease—TYK2—psoriasis	3.72e-06	0.000148	CbGpPWpGaD
Methotrexate—MTHFR—Disease—IL6—psoriasis	3.61e-06	0.000144	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—APOE—psoriasis	3.59e-06	0.000143	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PPARG—psoriasis	3.55e-06	0.000142	CbGpPWpGaD
Methotrexate—AOX1—Disease—IL6—psoriasis	3.53e-06	0.000141	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PPARG—psoriasis	3.38e-06	0.000135	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CD4—psoriasis	3.36e-06	0.000134	CbGpPWpGaD
Methotrexate—DHFR—Disease—IL6—psoriasis	3.21e-06	0.000128	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PPARG—psoriasis	3.13e-06	0.000125	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—VEGFA—psoriasis	2.95e-06	0.000118	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CAT—psoriasis	2.85e-06	0.000114	CbGpPWpGaD
Methotrexate—ABCC1—Disease—STAT3—psoriasis	2.6e-06	0.000104	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CAT—psoriasis	2.5e-06	9.97e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TP53—psoriasis	2.23e-06	8.89e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—APOE—psoriasis	2.21e-06	8.84e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—APOE—psoriasis	1.94e-06	7.74e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PPARG—psoriasis	1.93e-06	7.7e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—IL6—psoriasis	1.82e-06	7.26e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PPARG—psoriasis	1.69e-06	6.75e-05	CbGpPWpGaD
